Colistin Therapy in a 23-Week Gestational-Age Neonate with Multidrug-Resistant Acinetobacter baumannii Pneumonia

Abstract

Multidrug-resistant pathogens are becoming more difficult to treat with significantly increasing infection rates. The lack of new antibiotics to combat these strains has led to the resurgence of older antibiotics. This case highlights the first reported use of colistimethate sodium treatment in a 23-week gestational-age neonate with multidrug-resistant Acinetobacter baumannii pneumonia who developed acute renal failure and seizures shortly after initiation of treatment.

Keywords

Colistimethate - neonate - extremely low-birth-weight - multidrug resistant

• References

• 1 Wareham DW, Bean DC, Khanna P , et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27: 607-612
• 2 Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs 2009; 69: 1879-1901
• 3 Li J, Nation RL, Turnidge JD , et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601
• 4 Touati A, Achour W, Cherif A , et al. Outbreak of Acinetobacter baumannii in a neonatal intensive care unit: antimicrobial susceptibility and genotyping analysis. Ann Epidemiol 2009; 19: 372-378
• 5 Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006; 64: 7-15
• 6 Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25: 596-599
• 7 Choi JY, Park YS, Kim CO , et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35: 599-603
• 8 Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am 2009; 23: 1053-1075, x
• 9 Motaouakkil S, Charra B, Hachimi A , et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-278
• 10 Iosifidis E, Antachopoulos C, Ioannidou M , et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010; 169: 867-874
• 11 Montero M, Horcajada JP, Sorlí L , et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009; 37: 461-465
• 12 Hartzell JD, Neff R, Ake J , et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-1728
• 13 Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868
• 14 Santamaría C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P. Nephrotoxicity associated with the use of intravenous colistin. Scand J Infect Dis 2009; 41: 767-769
• 15 Naranjo CA, Busto U, Sellers EM , et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
• 16 Simmonds A, Munoz J, Aguero-Rosenfeld M , et al. Outbreak of Acinetobacter infection in extremely low birth weight neonates. Pediatr Infect Dis J 2009; 28: 210-214